90Yttrium (90Y)-Ibritumomab-Tiuxetan combines the target ing advantage of a monoclonal antibody with the radiosensitivity of Follicular Lymphoma (FL). Previous studies showed that 90Y-IT is safe and effective in relapsed/ refractory indolent FL, irrespective of prior treatment with rituximab. This multicentre trial aimed to evaluate the safety and the efficacy of “upfront” single-agent (90Y)-Ibritumomab-Tiuxetan in advanced-stage FL. The primary objective was the incidence of responses in terms of complete (CR) and partial remission (PR). Fifty patients with stage II “bulky”, III or IV FL received a single treatment course with (90Y)-Ibritumomab-Tiuxetan as initial therapy. The median age was 60 years. Bone marrow involvement (<25%) was observed in 24 patients (48%) and 7 (14%) had an elevated lactate dehydrogenase level. The overall response (ORR) and CR rates were 94% and 86%, respectively with a median follow-up of 388 months. The median progression-free survival (PFS) was not reached, whereas the 3-year estimated PFS and overall survival (OS) rate was 63 4% and 90%, respectively. Grade 3/4 neutropenia and thrombocytopenia occurred in 30% and26 % of patients respectively; none experienced grade 3/4 non-haematological toxicity. No cases of secondary haematological malignancies were observed. (90Y)-Ibritumomab-Tiuxetan was demonstrated to be highly effective and safe as first-line treatment for advanced-stage FL.

Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study

Petrini, Mario;Galimberti, Sara;Ciabatti, Elena;
2014-01-01

Abstract

90Yttrium (90Y)-Ibritumomab-Tiuxetan combines the target ing advantage of a monoclonal antibody with the radiosensitivity of Follicular Lymphoma (FL). Previous studies showed that 90Y-IT is safe and effective in relapsed/ refractory indolent FL, irrespective of prior treatment with rituximab. This multicentre trial aimed to evaluate the safety and the efficacy of “upfront” single-agent (90Y)-Ibritumomab-Tiuxetan in advanced-stage FL. The primary objective was the incidence of responses in terms of complete (CR) and partial remission (PR). Fifty patients with stage II “bulky”, III or IV FL received a single treatment course with (90Y)-Ibritumomab-Tiuxetan as initial therapy. The median age was 60 years. Bone marrow involvement (<25%) was observed in 24 patients (48%) and 7 (14%) had an elevated lactate dehydrogenase level. The overall response (ORR) and CR rates were 94% and 86%, respectively with a median follow-up of 388 months. The median progression-free survival (PFS) was not reached, whereas the 3-year estimated PFS and overall survival (OS) rate was 63 4% and 90%, respectively. Grade 3/4 neutropenia and thrombocytopenia occurred in 30% and26 % of patients respectively; none experienced grade 3/4 non-haematological toxicity. No cases of secondary haematological malignancies were observed. (90Y)-Ibritumomab-Tiuxetan was demonstrated to be highly effective and safe as first-line treatment for advanced-stage FL.
2014
Ibatici, Adalberto; Pica, Gian Matteo; Nati, Sandro; Vitolo, Umberto; Botto, Barbara; Ciochetto, Chiara; Petrini, Mario; Galimberti, Sara; Ciabatti, Elena; Orciuolo, Enrico; Zinzani, Pier Luigi; Cascavilla, Nicola; Guolo, Fabio; Fraternali Orcioni, Giulio; Carella, Angelo M.
File in questo prodotto:
File Dimensione Formato  
ibatici.pdf

accesso aperto

Tipologia: Versione finale editoriale
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 125.14 kB
Formato Adobe PDF
125.14 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/527870
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 28
  • ???jsp.display-item.citation.isi??? 29
social impact